Skip to content

Effect of intracoronary adenosine in patients with acute myocardial infarction

A clinical trial on the effectiveness of intracoronary adenosine for the prevention of no-reflow phenomenon in patients with acute myocardial infarction

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190112042329N1
Enrollment
126
Registered
2019-03-03
Start date
2019-03-21
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. Acute myocardial infarction

Interventions

Intervention 1: Control group: the control group will receive 3 mcg adenosine in 50 cc normal saline. Intervention 2: Intervention group: the low dose intervention group will receive 120 mcg adenosine

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Age higher than 20 years An elapse of 12 hours form the primary diagnosis

Exclusion criteria

Exclusion criteria: Having chronic obstructive pulmonary disease, asthma, less than 90 mm Hg systolic blood pressure, cardiac arrhythmia, sick sinus syndrome and neuropathy Candidates for coronary artery bypass grafts Using other medicines, such as verapamil

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events (i.e., mortality, second myocardial infarction, and stroke during admission). Timepoint: Before and 24 hours after the intervention. Method of measurement: Echocardiography.;Ejection fraction of ventricular. Timepoint: Before and 24 hours after the intervention. Method of measurement: Echocardiography.

Secondary

MeasureTime frame
The reduction of ST-segment. Timepoint: Before and 24 hours after the intervention. Method of measurement: Electrocardiogram (ECG).;Thrombolysis in myocardial infarction flow. Timepoint: Before and 24 hours after the intervention. Method of measurement: TIMI flow grading.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMustafa Baburian

Mashhad University of Medical Sciences

babourianm941@mums.ac.ir+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026